PRLR and EGFR/HER2 crosstalk, which greatly increases the activation of the RAS/ERK and PI3K/AKT pathways, are associated with poor prognosis and therapeutic resistance in breast tumor patients. Here, ERBB2 is linked to breast neoplasm.